Project Details


The MagnaPharm project, funded under the EU Horizon 2020 'Future and Emerging Technologies' programme, aims to direct polymorphism in pharmaceutical compounds by crystallizing them in high magnetic fields. The ability to direct polymorphism would have a transformative effect on almost all pharmaceutical compounds.

MagnaPharm builds on the discovery by Dr Simon Hall in the School of Chemistry that organic crystal growth can be controlled using magnetic fields. This innovative method will be applied to a range of pharmaceutical compounds, initially targeting 12 of the most high-profile, high-worth generic drugs with the aim of controllably synthesizing the desired polymorph of each (the lowest-energy polymorph and/or most processable form with desired properties).
Alternative titleMagnetic Control of Polymorphism in Pharmaceutical Compounds
Effective start/end date1/01/1731/12/19


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.